HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer
Interactions between immune and malignant cells have been known to have clinical relevance for decades. The potential for immune control is now being therapeutically enhanced with checkpoint inhibitors and other novel agents to improve outcomes in cancer. The importance of the immune infiltrate as a...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2017-08, Vol.117 (4), p.451-460 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 460 |
|---|---|
| container_issue | 4 |
| container_start_page | 451 |
| container_title | British journal of cancer |
| container_volume | 117 |
| creator | Barnes, Tristan A Amir, Eitan |
| description | Interactions between immune and malignant cells have been known to have clinical relevance for decades. The potential for immune control is now being therapeutically enhanced with checkpoint inhibitors and other novel agents to improve outcomes in cancer. The importance of the immune infiltrate as a prognostic marker is increasingly relevant. In this minireview, we present an overview of the immune infiltrate and its spatial organisation, and summarise the prognostic value of immune cells in different cancer types. International collaborative efforts are standardising histopathologic reporting of the immune infiltrate, to allow application of these parameters in the clinical and research settings. In general terms, a ‘pro-inflammatory’ tumour microenvironment and infiltrating CD8-expressing T lymphocytes are associated with improved clinical outcomes in a broad range of tumour types. The inhibitory function of other immune cells, for example, myeloid-derived suppressor cells and regulatory T cells, appear to have a major role in disrupting the capacity for the immune control of cancers. |
| doi_str_mv | 10.1038/bjc.2017.220 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5558691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1927602992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-22550975de39201e5ee75e5627d1803cb7922325a95d4069ee98ddd130842ed03</originalsourceid><addsrcrecordid>eNptkcFrFDEYxYModlu9eZaAFw-d9cs3m0nioSBldQuF9qAHT2E28-02y0yyJjMF_3uzbi1VPIWP9-PlPR5jbwTMBdT6w3rn5ghCzRHhGZsJWWMlNKrnbAYAqgKDcMJOc96V04BWL9kJagULvYAZu1p9v13ymPjq5nb5kY93xPcpbkPMo3f8vu0n4nHDfdj4fkzt6MOW-2GYAnFHfZ-Lwl0bHKVX7MWm7TO9fnjP2LfPy6-Xq-r65svV5afryknRjBWilGCU7KguwQRJIiVJNqg6oaF2a2UQa5Stkd0CGkNkdNd1oga9QOqgPmMXR9_9tB6ocxRKrt7ukx_a9NPG1tu_leDv7DbeWymlbowoBu8fDFL8MVEe7eDzoUwbKE7ZCoOqATQGC_ruH3QXpxRKvd-UUEKiLNT5kXIp5pxo8xhGgD1sZMtG9rCRLRsV_O3TAo_wn1EKUB2BXKSwpfTk1_8Z_gLULZmc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1927171525</pqid></control><display><type>article</type><title>HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>PubMed Central</source><creator>Barnes, Tristan A ; Amir, Eitan</creator><creatorcontrib>Barnes, Tristan A ; Amir, Eitan</creatorcontrib><description>Interactions between immune and malignant cells have been known to have clinical relevance for decades. The potential for immune control is now being therapeutically enhanced with checkpoint inhibitors and other novel agents to improve outcomes in cancer. The importance of the immune infiltrate as a prognostic marker is increasingly relevant. In this minireview, we present an overview of the immune infiltrate and its spatial organisation, and summarise the prognostic value of immune cells in different cancer types. International collaborative efforts are standardising histopathologic reporting of the immune infiltrate, to allow application of these parameters in the clinical and research settings. In general terms, a ‘pro-inflammatory’ tumour microenvironment and infiltrating CD8-expressing T lymphocytes are associated with improved clinical outcomes in a broad range of tumour types. The inhibitory function of other immune cells, for example, myeloid-derived suppressor cells and regulatory T cells, appear to have a major role in disrupting the capacity for the immune control of cancers.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2017.220</identifier><identifier>PMID: 28704840</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/327 ; 692/4028/67/580 ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer Research ; CD8 antigen ; CD8-Positive T-Lymphocytes ; Drug Resistance ; Epidemiology ; Humans ; Immune checkpoint ; Immunoregulation ; Inflammation ; Lymphocyte Subsets ; Lymphocytes ; Lymphocytes T ; Lymphocytes, Tumor-Infiltrating ; Medical prognosis ; mini-review ; Minireview ; Molecular Medicine ; Neoplasms - immunology ; Neoplasms - pathology ; Oncology ; Prognosis ; Reviews ; Suppressor cells ; Tumor microenvironment ; Tumor Microenvironment - immunology ; Tumors</subject><ispartof>British journal of cancer, 2017-08, Vol.117 (4), p.451-460</ispartof><rights>The Author(s) 2017</rights><rights>Copyright Nature Publishing Group Aug 8, 2017</rights><rights>Copyright © 2017 The Author(s) 2017 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-22550975de39201e5ee75e5627d1803cb7922325a95d4069ee98ddd130842ed03</citedby><cites>FETCH-LOGICAL-c516t-22550975de39201e5ee75e5627d1803cb7922325a95d4069ee98ddd130842ed03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558691/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558691/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27911,27912,41475,42544,51306,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28704840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barnes, Tristan A</creatorcontrib><creatorcontrib>Amir, Eitan</creatorcontrib><title>HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Interactions between immune and malignant cells have been known to have clinical relevance for decades. The potential for immune control is now being therapeutically enhanced with checkpoint inhibitors and other novel agents to improve outcomes in cancer. The importance of the immune infiltrate as a prognostic marker is increasingly relevant. In this minireview, we present an overview of the immune infiltrate and its spatial organisation, and summarise the prognostic value of immune cells in different cancer types. International collaborative efforts are standardising histopathologic reporting of the immune infiltrate, to allow application of these parameters in the clinical and research settings. In general terms, a ‘pro-inflammatory’ tumour microenvironment and infiltrating CD8-expressing T lymphocytes are associated with improved clinical outcomes in a broad range of tumour types. The inhibitory function of other immune cells, for example, myeloid-derived suppressor cells and regulatory T cells, appear to have a major role in disrupting the capacity for the immune control of cancers.</description><subject>631/67/327</subject><subject>692/4028/67/580</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immunoregulation</subject><subject>Inflammation</subject><subject>Lymphocyte Subsets</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Lymphocytes, Tumor-Infiltrating</subject><subject>Medical prognosis</subject><subject>mini-review</subject><subject>Minireview</subject><subject>Molecular Medicine</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - pathology</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Reviews</subject><subject>Suppressor cells</subject><subject>Tumor microenvironment</subject><subject>Tumor Microenvironment - immunology</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkcFrFDEYxYModlu9eZaAFw-d9cs3m0nioSBldQuF9qAHT2E28-02y0yyJjMF_3uzbi1VPIWP9-PlPR5jbwTMBdT6w3rn5ghCzRHhGZsJWWMlNKrnbAYAqgKDcMJOc96V04BWL9kJagULvYAZu1p9v13ymPjq5nb5kY93xPcpbkPMo3f8vu0n4nHDfdj4fkzt6MOW-2GYAnFHfZ-Lwl0bHKVX7MWm7TO9fnjP2LfPy6-Xq-r65svV5afryknRjBWilGCU7KguwQRJIiVJNqg6oaF2a2UQa5Stkd0CGkNkdNd1oga9QOqgPmMXR9_9tB6ocxRKrt7ukx_a9NPG1tu_leDv7DbeWymlbowoBu8fDFL8MVEe7eDzoUwbKE7ZCoOqATQGC_ruH3QXpxRKvd-UUEKiLNT5kXIp5pxo8xhGgD1sZMtG9rCRLRsV_O3TAo_wn1EKUB2BXKSwpfTk1_8Z_gLULZmc</recordid><startdate>20170808</startdate><enddate>20170808</enddate><creator>Barnes, Tristan A</creator><creator>Amir, Eitan</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170808</creationdate><title>HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer</title><author>Barnes, Tristan A ; Amir, Eitan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-22550975de39201e5ee75e5627d1803cb7922325a95d4069ee98ddd130842ed03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>631/67/327</topic><topic>692/4028/67/580</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immunoregulation</topic><topic>Inflammation</topic><topic>Lymphocyte Subsets</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Lymphocytes, Tumor-Infiltrating</topic><topic>Medical prognosis</topic><topic>mini-review</topic><topic>Minireview</topic><topic>Molecular Medicine</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - pathology</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Reviews</topic><topic>Suppressor cells</topic><topic>Tumor microenvironment</topic><topic>Tumor Microenvironment - immunology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barnes, Tristan A</creatorcontrib><creatorcontrib>Amir, Eitan</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barnes, Tristan A</au><au>Amir, Eitan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2017-08-08</date><risdate>2017</risdate><volume>117</volume><issue>4</issue><spage>451</spage><epage>460</epage><pages>451-460</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Interactions between immune and malignant cells have been known to have clinical relevance for decades. The potential for immune control is now being therapeutically enhanced with checkpoint inhibitors and other novel agents to improve outcomes in cancer. The importance of the immune infiltrate as a prognostic marker is increasingly relevant. In this minireview, we present an overview of the immune infiltrate and its spatial organisation, and summarise the prognostic value of immune cells in different cancer types. International collaborative efforts are standardising histopathologic reporting of the immune infiltrate, to allow application of these parameters in the clinical and research settings. In general terms, a ‘pro-inflammatory’ tumour microenvironment and infiltrating CD8-expressing T lymphocytes are associated with improved clinical outcomes in a broad range of tumour types. The inhibitory function of other immune cells, for example, myeloid-derived suppressor cells and regulatory T cells, appear to have a major role in disrupting the capacity for the immune control of cancers.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>28704840</pmid><doi>10.1038/bjc.2017.220</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2017-08, Vol.117 (4), p.451-460 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5558691 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature - Complete Springer Journals; Nature Journals Online; PubMed Central |
| subjects | 631/67/327 692/4028/67/580 Biomedical and Life Sciences Biomedicine Cancer Cancer Research CD8 antigen CD8-Positive T-Lymphocytes Drug Resistance Epidemiology Humans Immune checkpoint Immunoregulation Inflammation Lymphocyte Subsets Lymphocytes Lymphocytes T Lymphocytes, Tumor-Infiltrating Medical prognosis mini-review Minireview Molecular Medicine Neoplasms - immunology Neoplasms - pathology Oncology Prognosis Reviews Suppressor cells Tumor microenvironment Tumor Microenvironment - immunology Tumors |
| title | HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T11%3A34%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HYPE%20or%20HOPE:%20the%20prognostic%20value%20of%20infiltrating%20immune%20cells%20in%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Barnes,%20Tristan%20A&rft.date=2017-08-08&rft.volume=117&rft.issue=4&rft.spage=451&rft.epage=460&rft.pages=451-460&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/bjc.2017.220&rft_dat=%3Cproquest_pubme%3E1927602992%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1927171525&rft_id=info:pmid/28704840&rfr_iscdi=true |